Arcturus Therapeutics gains 5.8% on Thermo Fisher deal

By EC Assets · Published 2 July 2026

Arcturus Therapeutics Inc. shares increased by 5.8% in premarket trading on Thursday, July 2, 2026. This gain follows the announcement of a collaboration with Thermo Fisher Scientific. Arcturus Therapeutics Holdings Inc. has entered into a manufacturing and clinical research partnership with Thermo Fisher Scientific. The collaboration focuses on advancing ARCT-032 for cystic fibrosis. Arcturus Therapeutics will receive up to $3 million from Cystic Fibrosis Foundation Therapeutics for this LUNAR-formulated mRNA CFTR therapeutic. Freedom Broker initiated coverage on Arcturus Therapeutics with a Buy rating on July 2, 2026. Twelve analysts have set an average twelve-month price target for Arcturus Therapeutics at $25.44. Arcturus Therapeutics Holdings Inc. stock currently stands at $6.8900 as of 02:00. The stock experienced a change of +2.53% from the previous day. This article is intended for informational purposes only. It does not constitute investment advice.